Lonza

Speaking to BioPharm International, Michael De Marco, Vice President for Commercial Development in Integrated Biologics at Lonza, shared his perspective on the major trends and challenges in biopharma manufacturing. As a central takeaway he highlighted a shift toward regional supply strategies, alongside expected announcements on expanded manufacturing and research capacity. Maturing biotech pipelines may drive updates on potential launches, with new therapies reaching the market over the next 12–18 months. #Lonza #CDMO #Biologics #JPM

Meet Jacob Rossman, Senior Director, Operations, who started as an intern while completing a degree in Chemical and Bioengineering, and is now working as an End-to End Program Lead. After joining Lonza full-time, Jacob embraced opportunities for growth, earned an MBA , and advanced into leadership roles. Today, Jacob is helping transform our Vacaville site into a leading CDMO manufacturing facility. This work is about more than infrastructure, it’s about impact. “I’m deeply invested in what we do at Lonza: manufacturing lifesaving and life-extending medicines on a large scale. Through my work, I feel I can help so many patients around the world. In the CDMO industry, the impact we can have on people is tremendous, and Lonza is the best at it.” His advice for career growth? “Seek out roles where you can make an impact. Every challenge is an opportunity to learn and grow. At Lonza, things move quickly. When challenges arise and things get tough—keep going. You can always find the right forward path by being creative and working with the right people.” Learn more about careers at Lonza Careers https://ow.ly/lQEI50XVWvA #Lonza #CDMO #CareerGrowth #Opportunities

Fresh ideas to kick off 2026. 📬January’s “Advanced Synthesis in Focus” pulls together resources to help you move faster with confidence: • AI‑enabled cocrystal screening to de‑risk solid‑form selection early • Real‑world HME scale‑up tips for ASDs (vs. spray drying) • Greener synthesis via electrochemistry • How Design2Optimize™ and route scouting are cutting complexity and avoiding rework. Read the full newsletter below and subscribe to monthly updates. #DrugDevelopment #Lonza #PharmaInnovation #CDMO

Our Specialized Modalities team is at the 2026 at the J.P. Morgan Healthcare Conference in San Francisco, January 12–15. We'll be on the ground to talk with you about how we can support your goals in the new year. If you’re attending and would like to meet, send us a direct message to request time in advance, or reach out to your usual account contact. 🤝 Request a meeting with our team: https://lnkd.in/eMYDVTmU

Speaking to Pharma's Almanac, Atul Mohindra, Vice President for R&D in Integrated Biologics at Lonza, shared his thoughts on which advance has had the greatest impact on the industry over the last 30 years. He explains why advancements in digital technologies such as process analytical technologies (PAT) have helped to accelerate drug development by solving complexities and bottlenecks in the supply chain and quality, especially for highly complex biologics. Read the full article here: https://lnkd.in/edXxxxSi #Lonza #CDMO #Innovation #Biologics

We are heading to PepTalk 2026 in San Diego, and we’re excited to share new advances in biotherapeutic protein expression. 🔬✨ Join us on Tuesday, January 20 at 3:05 PM (PT) for a presentation by Peter O'Callaghan, Ph.D., Head of Expression System Sciences, titled: Advanced vector platforms for enhanced biotherapeutic protein expression In this session, Dr. O’Callaghan will unveil GSquad® Pro, Lonza’s next-generation expression vector platform, and its newly engineered LHP-1 high-performance promoter. You’ll learn how optimized vector design — particularly promoter selection — can dramatically influence: ✔️ Product titer ✔️ Product quality ✔️ Long-term expression stability He’ll also share insights from Lonza’s growing, industry-leading datasets on CHO gene expression control, and how these learnings are driving continued innovation in vector engineering. If you’re attending PepTalk, we invite you to join the session and connect with our team to discuss how advanced vector design can accelerate and strengthen your biomanufacturing programs. Learn more about our Expression Technologies https://lnkd.in/dsJdCz3k See you in San Diego! #Lonza #PepTalk2026 #ProteinExpression #Biologics #GSquadPro #CHO #Bioprocessing #InYoutLab #ExpressionTechnologies

🚀 We’re kicking off 2026 at the J.P. Morgan Healthcare Conference in San Francisco, January 12–15. Our team will be on the ground to listen, learn, and explore how we can support your goals in the year ahead—from early development through to scale. If you’re planning to attend and would like to meet, send us a direct message to request time in advance, or reach out to your usual account contact. 🤝 You can request a meeting with our team here: https://ow.ly/8T4850XK9f9. #JPMorganHealthcareConference #Biotech #PharmaInnovation

Reflecting on a year of insight and innovation in biologics development. As 2025 comes to a close, we’re taking a moment to thank our scientists and experts who shared their perspectives through our CDMO Notes blog https://lnkd.in/gMprg-bZ. Each article explored key challenges and innovations shaping the future of biologics manufacturing — from accelerating timelines to refining analytical methods. 👏 Thank you to our 2025 contributors: - Nicholas Field, Ph.D. – High-Throughput Chromatography: The Key to Unlocking Downstream Development of New Molecular Format Biologics https://lnkd.in/dADPKGCd - Sanjukta Chatterjee, Ph.D. – 384-Well High-Throughput ELISA Method for Host Cell Protein Analysis https://lnkd.in/da73J36h - Oktawia Borkowska – Navigating Host Cell Protein Bridging Challenges https://lnkd.in/dwEbx_G5 - Jennifer Newman– Analytical Methods to Accelerate New Molecular Formats https://lnkd.in/dDXjxcpt - Yusuf Johari, Ph.D. – Optimizing Therapeutic Protein Expression https://lnkd.in/de2Grsvt - Carreira Cintia Carreira, Ph.D. – Bespoke Downstream Processing Strategies https://lnkd.in/dUSdFEFs - Alejandro Fernandez-Martell, Ph.D. – Accelerating the Timeline to Tox Material https://lnkd.in/dRxPbyzs - Andrew Brown, Eng.D. – An Accelerated Approach to Drug Development https://lnkd.in/drW2f_HS 🔍 Subscribe to our CDMO Notes Blog newsletter to stay informed on the continued collaboration and innovation articles ahead in 2026: https://lnkd.in/gMprg-bZ #CDMONotesBlog #Biologics #Innovation #DrugDevelopment #Lonza

As we wrap up an incredible year, we want to thank you for being part of our journey! Looking for inspiration during the holiday downtime? Here are five hot topics your peers loved this year: ✅ Unlock the future of drug development ( https://bit.ly/48WDIHN ) Physiologically Based Biopharmaceutics Modeling and solid form screening—boost bioavailability and accelerate First-in-Human studies. ✅ Bringing novel ADC formats into the clinic ( https://bit.ly/4qbRH3s ) Practical process insights for antibody-oligonucleotide conjugates. ✅ Lonza’s integrated ADC offering ( https://bit.ly/3KPL1t4 ) End-to-end strategies that simplify the path from concept to commercialization. ✅ Continuous flow techniques for pharma manufacturing ( https://bit.ly/3KMfLLv ) Real case studies on boosting yield, cutting costs, and improving robustness. ✅ Streamlining early-phase drug development ( https://bit.ly/3L1xP4l ) How continuous flow and AI-enabled route scouting improve speed, safety, and robustness. We’re excited to continue this journey together in the new year!

🚀 Weekend reading: AI does the heavy lifting to simplify early-stage drug development Moving a therapy from lab to market has always been complex — and with APIs becoming more intricate, the challenge is bigger than ever. That’s where AI-enabled tools come in. From route scouting to smarter experimental design, predictive models are helping researchers make better decisions faster, reduce risks, and accelerate timelines. Discover how Lonza is using AI to simplify the journey for even the most complex molecules: 👉 https://ow.ly/A2mJ50XIlmS #DrugDevelopment #PharmaInnovation #Lonza